Aberdeen Group
TVTX icon

Aberdeen Group’s Travere Therapeutics TVTX Stock Holding History

Aberdeen Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.09M Sell
124,855
-432,292
-78% -$19.2M 0.01% 651
2026
Q1 		$16.6M Buy
557,147
+38,790
+7% +$1.16M 0.03% 474
2025
Q4 		$19.8M Sell
518,357
-449,028
-46% -$14.6M 0.03% 433
2025
Q3 		$23.1M Buy
967,385
+70,791
+8% +$1.33M 0.04% 383
2025
Q2 		$13.3M Buy
896,594
+416,225
+87% +$6.9M 0.02% 534
2025
Q1 		$8.61M Buy
480,369
+88,369
+23% +$1.79M 0.02% 594
2024
Q4 		$6.83M Buy
+392,000
New +$6.93M 0.01% 588

Other funds holding TVTX

SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Aberdeen Group's TVTX Position: Q2 2026 in Review

Aberdeen Group reduced its Travere Therapeutics (TVTX) stake by 78% in Q2 2026, selling an estimated $19.2M and leaving 124,855 shares worth $7.09M. The position accounts for 0.01% of the portfolio, ranked #651.

Aberdeen Group first reported a position in TVTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $23.1M in Q3 2025. 55 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Aberdeen Group held 124,855 shares of Travere Therapeutics worth $7.09M as of Q2 2026.
  • Aberdeen Group sold 432,292 Travere Therapeutics shares in Q2 2026, an estimated $19.2M.
  • Travere Therapeutics made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #651 holding.
  • Aberdeen Group first reported a position in Travere Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Aberdeen Group's Travere Therapeutics position peaked at $23.1M in Q3 2025.
  • 55 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.